{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T12:46:41Z","timestamp":1785847601653,"version":"3.56.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"INCa-Canc\u00e9rop\u00f4le","award":["No. 2018-E13"],"award-info":[{"award-number":["No. 2018-E13"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10549-026-08041-0","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:13:37Z","timestamp":1785258817000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antacid co-treatment and pregnane X receptor genetic polymorphisms are survival determinants in patients treated with palbociclib"],"prefix":"10.1007","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9404-5044","authenticated-orcid":false,"given":"Fanny","family":"Leenhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Jacot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Lellouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Guiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Viala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Firmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Payen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litaty C.","family":"Mbatchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Fiteni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Evrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"8041_CR1","doi-asserted-by":"publisher","unstructured":"Roncato R, Angelini J, Pani A, Cecchin E, Sartore-Bianchi A, Siena S et al (2020) CDK4\/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions. Int J Mol Sci 21. https:\/\/doi.org\/10.3390\/ijms21176350","DOI":"10.3390\/ijms21176350"},{"key":"8041_CR2","doi-asserted-by":"publisher","first-page":"105812","DOI":"10.1016\/j.ejps.2021.105812","volume":"162","author":"Z Vinarov","year":"2021","unstructured":"Vinarov Z, Abdallah M, Agundez JAG, Allegaert K, Basit AW, Braeckmans M et al (2021) Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. Eur J Pharm Sci Off J Eur Fed Pharm Sci 162:105812. https:\/\/doi.org\/10.1016\/j.ejps.2021.105812","journal-title":"Eur J Pharm Sci Off J Eur Fed Pharm Sci"},{"key":"8041_CR3","doi-asserted-by":"publisher","first-page":"100880","DOI":"10.1016\/j.esmoop.2023.100880","volume":"8","author":"JL Raoul","year":"2023","unstructured":"Raoul JL, Moreau-Bachelard C, Gilabert M, Edeline J, Fr\u00e9nel JS (2023) Drug-drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure. ESMO Open 8:100880. https:\/\/doi.org\/10.1016\/j.esmoop.2023.100880","journal-title":"ESMO Open"},{"key":"8041_CR4","doi-asserted-by":"publisher","first-page":"100231","DOI":"10.1016\/j.esmoop.2021.100231","volume":"6","author":"M Del Re","year":"2021","unstructured":"Del Re M, Omarini C, Diodati L, Palleschi M, Meattini I, Crucitta S et al (2021) Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open 6:100231. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100231","journal-title":"ESMO Open"},{"key":"8041_CR5","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/cpdd.356","volume":"6","author":"W Sun","year":"2017","unstructured":"Sun W, Klamerus KJ, Yuhas LM, Pawlak S, Plotka A, O\u2019Gorman M et al (2017) Impact of Acid-Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH-Dependent Solubility, With Different Food Intake Conditions. Clin Pharmacol Drug Dev 6:614\u2013626. https:\/\/doi.org\/10.1002\/cpdd.356","journal-title":"Clin Pharmacol Drug Dev"},{"key":"8041_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrd705","volume":"1","author":"DM Roden","year":"2002","unstructured":"Roden DM, George AL (2002) The genetic basis of variability in drug responses. Nat Rev Drug Discov 1:37\u201344. https:\/\/doi.org\/10.1038\/nrd705","journal-title":"Nat Rev Drug Discov"},{"key":"8041_CR7","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3390\/pharmaceutics14071317","volume":"14","author":"P Courlet","year":"2022","unstructured":"Courlet P, Cardoso E, Bandiera C, Stravodimou A, Zurcher J-P, Chtioui H et al (2022) Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer. Pharmaceutics 14:1317. https:\/\/doi.org\/10.3390\/pharmaceutics14071317","journal-title":"Pharmaceutics"},{"key":"8041_CR8","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.tox.2006.12.019","volume":"231","author":"X Chen","year":"2007","unstructured":"Chen X, Zhang J, Baker SM, Chen G (2007) Human constitutive androstane receptor mediated methotrexate induction of human dehydroepiandrosterone sulfotransferase (hSULT2A1). Toxicology 231:224\u2013233. https:\/\/doi.org\/10.1016\/j.tox.2006.12.019","journal-title":"Toxicology"},{"key":"8041_CR9","doi-asserted-by":"publisher","first-page":"e1143","DOI":"10.1002\/onco.13811","volume":"26","author":"H Iwata","year":"2021","unstructured":"Iwata H, Umeyama Y, Liu Y, Zhang Z, Schnell P, Mori Y et al (2021) Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2\/-3. Oncologist 26:e1143\u2013e1155. https:\/\/doi.org\/10.1002\/onco.13811","journal-title":"Oncologist"},{"key":"8041_CR10","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3390\/pharmaceutics14040841","volume":"14","author":"F Leenhardt","year":"2022","unstructured":"Leenhardt F, Fiteni F, Gauthier L, Alexandre M, Guiu S, Firmin N et al (2022) Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug-Drug Interactions Are the Usual Suspects. Pharmaceutics 14:841. https:\/\/doi.org\/10.3390\/pharmaceutics14040841","journal-title":"Pharmaceutics"},{"key":"8041_CR11","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3390\/biom11081142","volume":"11","author":"A Skandalaki","year":"2021","unstructured":"Skandalaki A, Sarantis P, Theocharis S (2021) Pregnane X, Receptor (PXR) Polymorphisms and Cancer Treatment. Biomolecules 11:1142. https:\/\/doi.org\/10.3390\/biom11081142","journal-title":"Biomolecules"},{"key":"8041_CR12","doi-asserted-by":"publisher","unstructured":"Tulay K, Aktas G, Kalender ME, Demiry\u00fcrek AT, Ulasl\u0131 M, Oztuzcu S et al (2016) Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. OncoTargets and Therapy 9:5073\u20135080. https:\/\/doi.org\/10.2147\/OTT.S106574","DOI":"10.2147\/OTT.S106574"},{"key":"8041_CR13","doi-asserted-by":"publisher","first-page":"v96","DOI":"10.1093\/annonc\/mdx365.054","volume":"28","author":"V Di\u00e9ras","year":"2017","unstructured":"Di\u00e9ras V, Harbeck N, Joy AA, Gelmon KA, Ettl J, Verma S et al (2017) PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor\u2013positive (ER+)\/human epidermal growth factor receptor 2\u2009\u2013\u2009negative (HER2\u2013) first-line advanced breast cancer (ABC) receiving palbociclib\u2009+\u2009letrozole (P\u2009+\u2009L). Ann Oncol 28:v96. https:\/\/doi.org\/10.1093\/annonc\/mdx365.054","journal-title":"Ann Oncol"},{"key":"8041_CR14","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41416-020-0967-7","volume":"123","author":"NP McAndrew","year":"2020","unstructured":"McAndrew NP, Dickson MA, Clark AS, Troxel AB, O\u2019Hara MH, Colameco C et al (2020) Early treatment-related neutropenia predicts response to palbociclib. Br J Cancer 123:912\u2013918. https:\/\/doi.org\/10.1038\/s41416-020-0967-7","journal-title":"Br J Cancer"},{"key":"8041_CR15","doi-asserted-by":"publisher","first-page":"103761","DOI":"10.1016\/j.breast.2024.103761","volume":"76","author":"S Di Cosimo","year":"2024","unstructured":"Di Cosimo S, P\u00e9rez-Garc\u00eda JM, Bellet M, Dalenc F, Gil Gil MJ, Ruiz-Borrego M et al (2024) Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive\/HER2-negative advanced breast cancer. Breast 76:103761. https:\/\/doi.org\/10.1016\/j.breast.2024.103761","journal-title":"Breast"},{"key":"8041_CR16","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1177\/10781552241269677","volume":"31","author":"J \u00c1lvarez Criado","year":"2025","unstructured":"\u00c1lvarez Criado J, Zamora Au\u00f1on P, Mart\u00ednez Mar\u00edn V, Garc\u00edaTrevijano Cabetas M, Collada S\u00e1nchez VL, Espinosa Arranz E et al (2025) Proton pump inhibitors decrease efficacy of palbociclib in patients with metastatic breast. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract 31:795\u2013802. https:\/\/doi.org\/10.1177\/10781552241269677","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"key":"8041_CR17","doi-asserted-by":"publisher","first-page":"102794","DOI":"10.1016\/j.ctrv.2024.102794","volume":"129","author":"J-L Raoul","year":"2024","unstructured":"Raoul J-L, Hansten PD (2024) Proton pump inhibitors and cancer treatments: Emerging evidence against coadministration. Cancer Treat Rev 129:102794. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102794","journal-title":"Cancer Treat Rev"},{"key":"8041_CR18","doi-asserted-by":"publisher","first-page":"1352224","DOI":"10.3389\/fphar.2024.1352224","volume":"15","author":"FCA de Moraes","year":"2024","unstructured":"de Moraes FCA, Pereira CRM, Sano VKT, Laia EAD, Stecca C, Burbano RMR (2024) Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4\/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis. Front Pharmacol 15:1352224. https:\/\/doi.org\/10.3389\/fphar.2024.1352224","journal-title":"Front Pharmacol"},{"key":"8041_CR19","doi-asserted-by":"publisher","first-page":"119893","DOI":"10.1016\/j.cca.2024.119893","volume":"562","author":"RMR Kumar","year":"2024","unstructured":"Kumar RMR, Joghee S (2024) Enhancing breast cancer treatment through pharmacogenomics: A narrative review. Clin Chim Acta 562:119893. https:\/\/doi.org\/10.1016\/j.cca.2024.119893","journal-title":"Clin Chim Acta"},{"key":"8041_CR20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/14622416.2024.2380240","volume":"25","author":"C Wang","year":"2024","unstructured":"Wang C, Hwang M, Paulson B, Mhandire D, Ozair S, O\u2019Connor TL et al (2024) Potential association of SULT2A1 and ABCG2 variant alleles with increased risk for palbociclib toxicity. Pharmacogenomics 25:367\u2013375. https:\/\/doi.org\/10.1080\/14622416.2024.2380240","journal-title":"Pharmacogenomics"},{"key":"8041_CR21","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s40262-016-0392-5","volume":"55","author":"LC Mbatchi","year":"2016","unstructured":"Mbatchi LC, Robert J, Ychou M, Boyer J-C, Del Rio M, Gassiot M et al (2016) Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients. Clin Pharmacokinet 55:1145\u20131157. https:\/\/doi.org\/10.1007\/s40262-016-0392-5","journal-title":"Clin Pharmacokinet"},{"key":"8041_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2217\/pgs-2019-0127","volume":"21","author":"H le Ba","year":"2020","unstructured":"le Ba H, Mbatchi L, Gattacceca F, Evrard A, Lacarelle B, Blanchet B et al (2020) Pharmacogenetics and pharmacokinetics modeling of unexpected and extremely severe toxicities after sorafenib intake. Pharmacogenomics 21:173\u2013179. https:\/\/doi.org\/10.2217\/pgs-2019-0127","journal-title":"Pharmacogenomics"},{"key":"8041_CR23","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/bjc.2012.548","volume":"108","author":"B Beuselinck","year":"2013","unstructured":"Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G et al (2013) Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 108:887\u2013900. https:\/\/doi.org\/10.1038\/bjc.2012.548","journal-title":"Br J Cancer"},{"key":"8041_CR24","doi-asserted-by":"publisher","first-page":"115479","DOI":"10.1016\/j.biopha.2023.115479","volume":"167","author":"E Peruzzi","year":"2023","unstructured":"Peruzzi E, Gerratana L, Montico M, Posocco B, Corsetti S, Bartoletti M et al (2023) Association of ADME gene polymorphisms on toxicity to CDK4\/6 inhibitors in patients with HR+ HER2- metastatic breast cancer. Biomed Pharmacother Biomedecine Pharmacother 167:115479. https:\/\/doi.org\/10.1016\/j.biopha.2023.115479","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"key":"8041_CR25","doi-asserted-by":"publisher","first-page":"897951","DOI":"10.3389\/fphar.2022.897951","volume":"13","author":"R Roncato","year":"2022","unstructured":"Roncato R, Gerratana L, Palmero L, Gagno S, Poetto AS, Peruzzi E et al (2022) An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4\/6 Inhibitors for Metastatic Breast Cancer. Front Pharmacol 13:897951. https:\/\/doi.org\/10.3389\/fphar.2022.897951","journal-title":"Front Pharmacol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08041-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08041-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08041-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:54:11Z","timestamp":1785844451000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08041-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8041"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08041-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Trial registration: NCT04025541.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Trial registration: NCT04025541.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"20"}}